211 related articles for article (PubMed ID: 19790235)
21. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
22. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines.
Cronauer MV; Schulz WA; Ackermann R; Burchardt M
Int J Oncol; 2005 Apr; 26(4):1033-40. PubMed ID: 15753999
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of androgen receptor and β-catenin activity in prostate cancer.
Lee E; Madar A; David G; Garabedian MJ; Dasgupta R; Logan SK
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15710-5. PubMed ID: 24019458
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.
Litvinov IV; Vander Griend DJ; Antony L; Dalrymple S; De Marzo AM; Drake CG; Isaacs JT
Proc Natl Acad Sci U S A; 2006 Oct; 103(41):15085-90. PubMed ID: 17015840
[TBL] [Abstract][Full Text] [Related]
26. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor.
Fan W; Yanase T; Morinaga H; Okabe T; Nomura M; Daitoku H; Fukamizu A; Kato S; Takayanagi R; Nawata H
J Biol Chem; 2007 Mar; 282(10):7329-38. PubMed ID: 17202144
[TBL] [Abstract][Full Text] [Related]
28. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
[TBL] [Abstract][Full Text] [Related]
29. Intracellular adaptor molecules and AR signalling in the tumour microenvironment.
Reebye V; Frilling A; Habib NA; Mintz PJ
Cell Signal; 2011 Jun; 23(6):1017-21. PubMed ID: 21130868
[TBL] [Abstract][Full Text] [Related]
30. The oncogenic potential of a prostate cancer-derived androgen receptor mutant.
Shi XB; Xue L; Tepper CG; Gandour-Edwards R; Ghosh P; Kung HJ; DeVere White RW
Prostate; 2007 May; 67(6):591-602. PubMed ID: 17262801
[TBL] [Abstract][Full Text] [Related]
31. Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model.
Chang HH; Chen BY; Wu CY; Tsao ZJ; Chen YY; Chang CP; Yang CR; Lin DP
J Biomed Sci; 2011 Jan; 18(1):6. PubMed ID: 21241512
[TBL] [Abstract][Full Text] [Related]
32. Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
Vummidi Giridhar P; Williams K; VonHandorf AP; Deford PL; Kasper S
Cancer Res; 2019 Mar; 79(6):1124-1137. PubMed ID: 30626627
[TBL] [Abstract][Full Text] [Related]
33. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation.
Vander Griend DJ; Litvinov IV; Isaacs JT
Cell Cycle; 2007 Mar; 6(6):647-51. PubMed ID: 17387277
[TBL] [Abstract][Full Text] [Related]
34. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor.
Nishida S; Hirohashi Y; Torigoe T; Inoue R; Kitamura H; Tanaka T; Takahashi A; Asanuma H; Masumori N; Tsukamoto T; Sato N
Cancer Sci; 2013 Apr; 104(4):431-6. PubMed ID: 23320511
[TBL] [Abstract][Full Text] [Related]
36. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
37. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
Leach DA; Need EF; Toivanen R; Trotta AP; Palethorpe HM; Tamblyn DJ; Kopsaftis T; England GM; Smith E; Drew PA; Pinnock CB; Lee P; Holst J; Risbridger GP; Chopra S; DeFranco DB; Taylor RA; Buchanan G
Oncotarget; 2015 Jun; 6(18):16135-50. PubMed ID: 25965833
[TBL] [Abstract][Full Text] [Related]
38. p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).
Liu T; Li Y; Gu H; Zhu G; Li J; Cao L; Li F
J Biol Chem; 2013 Feb; 288(5):3359-69. PubMed ID: 23132866
[TBL] [Abstract][Full Text] [Related]
39. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
40. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
